The Clinical Study of Dexmedetomidine and Esketamine Combined Infusion Undergoing Modified Radical Mastectomy
Status:
Recruiting
Trial end date:
2023-06-30
Target enrollment:
Participant gender:
Summary
BACKGROUND: Some studies have revealed that intravenous dexmedetomidine and esketamine
alleviated postoperative pain and improve the quality of recovery after surgery. The
investigators investigated whether co-administration dexmedetomidine and esketamine could
better alleviated postoperative pain and improve the the quality of recovery after modified
radical mastectomy.
METHODS: One hundred and thirty-five women with elective modified radical mastectomy were
randomly divided into 3 groups: Patients in group D received dexmedetomidine (0.5 µg/kg over
10 min before the induction of anesthesia), and then dexmedetomidine was infused at a rate of
0.4 μg/kg/h until 20 min before the end of operation. Patients in group DE1 received a bolus
infusion of dexmedetomidine (0.5 µg/kg) and esketamine (0.5 mg/kg)over 10 min before the
induction of anesthesia, and then dexmedetomidine were infused at a rate of 0.4 µg/kg/h and 2
µg/kg/min until 20 min before the end of operation, respectively. Patients in group DE2
received received a bolus infusion of dexmedetomidine (0.5 µg/kg) and esketamine (0.5
mg/kg)over 10 min before the induction of anesthesia, and then dexmedetomidine were infused
at a rate of 0.4 µg/kg/h and 4 µg/kg/min until 20 min before the end of operation,
respectively. Primary outcome was the quality of recovery (QoR-15) at 1 day after sugery and
3 day after sugery. The secondary outcomes included perioperative remifentanil consumption,
postoperative VAS pain scores, side effects such as the incidence of postoperative nausea,
vomiting and bradycardia, hallucination, nightmare, as well as postoperative rescue
analgesics and anti-emetics, recovery time, and extubation time.